Disease · MONDO_0010643
Targets246
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 246
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 5 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 4 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 4 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| RRM1 | Ribonucleoside-diphosphate reductase RR1 | 4 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6240 | Drugs and targets |
| RRM2 | Ribonucleoside-diphosphate reductase RR1 | 4 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase small subunit mRNA antisense inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6241 | Drugs and targets |
| RRM2B | Ribonucleoside-diphosphate reductase RR1 | 4 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/50484 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7277 | Drugs and targets |
| TUBB | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/203068 | Drugs and targets |
| TUBB1 | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/81027 | Drugs and targets |
| TUBB2A | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7280 | Drugs and targets |
| TUBB2B | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/347733 | Drugs and targets |
| TUBB3 | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/10381 | Drugs and targets |
| TUBB4A | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/10382 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010643/targets